|
Volumn 351, Issue , 2015, Pages
|
New Pacific trade deal - Good for pharma, bad for public health?
a
NONE
(United Kingdom)
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ATOMOXETINE;
OLANZAPINE;
ARTICLE;
ATTENTION DEFICIT DISORDER;
DRUG COST;
DRUG INDUSTRY;
ECONOMIC DEVELOPMENT;
GOVERNMENT;
GROSS NATIONAL PRODUCT;
HEALTH HAZARD;
HUMAN;
INVESTMENT;
LAW;
NATIONAL HEALTH SERVICE;
PATENT;
PRIORITY JOURNAL;
PROFIT;
PUBLIC HEALTH;
TAX;
TRADE UNION;
TRANS PACIFIC PARTNERSHIP;
UNITED STATES;
AUSTRALIA;
BRUNEI DARUSSALAM;
CANADA;
CHILE;
COMMERCIAL PHENOMENA;
CONTRACT;
ECONOMICS;
HEALTH CARE POLICY;
INTERNATIONAL COOPERATION;
JAPAN;
MALAYSIA;
MEXICO;
NEW ZEALAND;
PERU;
SINGAPORE;
VIET NAM;
AUSTRALIA;
BRUNEI;
CANADA;
CHILE;
COMMERCE;
CONTRACTS;
DRUG INDUSTRY;
HEALTH POLICY;
HUMANS;
INTERNATIONAL COOPERATION;
INVESTMENTS;
JAPAN;
MALAYSIA;
MEXICO;
NEW ZEALAND;
PERU;
PUBLIC HEALTH;
SINGAPORE;
UNITED STATES;
VIETNAM;
|
EID: 84940112091
PISSN: 09598146
EISSN: 17561833
Source Type: Journal
DOI: 10.1136/bmj.h3649 Document Type: Article |
Times cited : (3)
|
References (15)
|